Department of Immunology and Rheumatology, Sichuan University, Chengdu, People's Republic of China.
Int Orthop. 2011 Sep;35(9):1409-14. doi: 10.1007/s00264-010-1062-0. Epub 2010 Jun 13.
The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease. Adults (n = 168) with Kashin-Beck disease were randomised in clusters to receive six week courses of celecoxib 200 mg once daily, meloxicam 7.5 mg once daily or paracetamol 300 mg three times daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Celecoxib and meloxicam were efficacious in relieving pain and improving stiffness, but unable to improve physical function after six weeks. Paracetamol was efficacious in relieving pain, but unable to improve morning stiffness and physical function after six weeks. Celecoxib and meloxicam provide predictable and sustained relief from pain and stiffness. Paracetamol can relieve the pain. None of the treatments improved impaired physical function in Kashin-Beck disease.
本研究旨在比较塞来昔布、美洛昔康和对乙酰氨基酚治疗晚发性大骨节病的疗效和耐受性。将 168 例大骨节病患者按簇随机分为塞来昔布 200mg 每日 1 次、美洛昔康 7.5mg 每日 1 次和对乙酰氨基酚 300mg 每日 3 次 6 周疗程组。疗效评估包括关节疼痛总强度和西安大略和麦克马斯特大学骨关节炎指数亚量表；通过不良事件和医生报告评估耐受性。塞来昔布和美洛昔康可有效缓解疼痛和改善僵硬，但 6 周后无法改善躯体功能。对乙酰氨基酚可有效缓解疼痛，但 6 周后无法改善晨僵和躯体功能。塞来昔布和美洛昔康可提供可预测和持续的疼痛和僵硬缓解。对乙酰氨基酚可以缓解疼痛。治疗均无法改善大骨节病患者的躯体功能受损。
